Skip to content

Author

Sarah T. Diepstraten

We have 2 of 39 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

A high-density CRISPR activation platform for mapping cancer dependencies and resistance pathways ex vivo and in vivo

Partita, a next-generation mouse whole-genome CRISPRa sgRNA platform, designed for unparalleled efficiency in gene activation studies, is introduced, unlocking new avenues for functional genomics and expanding the toolkit for discovering key drivers of biological processes across diverse research fields.

Sarah T. Diepstraten, Yexuan Deng, Margaret A. Potts et al. · 0 citations
Open access Sep 2026

γδ T cells modulate anti-tumor immunity in small cell lung cancer.

It is demonstrated that γδ T cells are effective at tarlatamab (delta-like ligand 3 [DLL3]-CD3 bispecific T cell engager [BiTE])-redirected SCLC killing and that zoledronate can sensitize SCLC cells to γδ T cell-mediated killing.

Jin Ng, Yue You, Tina Zhang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.